Keyphrases
Aged 80 Years and over
28%
Antidepressant Use
28%
Bacteremia
28%
Chronic Intestinal Failure
60%
Cirrhosis
41%
Cognitive Impairment
28%
Critical Flicker Frequency
28%
Crohn's Disease
70%
Dasabuvir
28%
Diagnostic Performance
28%
Disease Development
28%
Duodenal-jejunal Bypass Liner
28%
Emergency Department
28%
Endoscopic Retrograde Cholangiopancreatography
28%
Endoscopic Ultrasound
28%
Failure Management
28%
Gastrointestinal Diseases
31%
Hepatitis C
56%
Hepatitis C Virus
84%
Hepatocellular Carcinoma
33%
Home Parenteral nutrition
78%
Host Factors
28%
Host Response
28%
Inflammatory Bowel Disease
28%
Intestinal Failure
44%
Intravenous Supplementation
28%
Motility
32%
Multicenter Trial
28%
National Reference Center
28%
Nonagenarians
28%
Old Age
28%
Older Patients
28%
Ombitasvir
28%
Optical Coherence Tomography Angiography (OCT-A)
28%
Paritaprevir
28%
Patient Assessment
28%
Patient Understanding
28%
Patient-reported Outcomes
28%
Plasma Vitamin C
28%
Protease Inhibitors
33%
R353Q
28%
Recurrent Disease
28%
Response to Therapy
28%
Ribavirin
28%
Risk Factors
44%
Ritonavir
28%
Small Intestine
40%
Strong Opioids
28%
Video Capsule Endoscopy
31%
Viral Factors
28%
Medicine and Dentistry
Adverse Event
23%
Antidepressant
28%
Ascorbic Acid
28%
Bile Acid
28%
Bleeding
14%
Bloodstream Infection
28%
Body Mass Index
18%
Cancer
13%
Capsule Endoscopy
33%
Catheter Infection
32%
Chronic Liver Disease
15%
Clinician
18%
Cohort Analysis
31%
Crohn's Disease
66%
Dasabuvir
28%
Diabetes Mellitus
28%
Diseases
30%
Emergency Department
28%
Endoscopic Retrograde Cholangiopancreatography
28%
Endoscopic Ultrasound
28%
Endoscopy
18%
Functional Gastrointestinal Disorder
18%
Gene Linkage
28%
Glycemic Control
28%
Gut
47%
Hepatitis C
33%
Hepatitis C Virus
56%
Hepatitis C Virus Genotype 1
14%
Hepatocellular Carcinoma
33%
Home Parenteral Nutrition
99%
Ingestion
28%
Intestinal Failure
100%
Liver Cirrhosis
41%
Liver Disease
33%
Logistic Regression Analysis
19%
Malabsorption
18%
Nonalcoholic Fatty Liver
12%
Nutritional Status
28%
Odds Ratio
16%
Ombitasvir
28%
Paritaprevir
28%
Patient with Crohn's Disease
37%
Patient with Obesity
28%
Prevalence
23%
Proteinase Inhibitor
28%
Recurrent Disease
30%
Ribavirin
28%
Ritonavir
28%
Side Effect
14%
Supplementation
26%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
42%
Alpha Tocopherol
14%
Analgesic Agent
9%
Antibiotic Prophylaxis
28%
Antiviral Therapy
13%
Antivirus Agent
8%
Ascorbic Acid
28%
Bisacodyl
5%
Bloodstream Infection
28%
Catheter Infection
32%
Chronic Hepatitis C
5%
Chronic Liver Disease
15%
Chronicity
9%
Cognitive Defect
28%
Combination Therapy
5%
Crohn's Disease
84%
Dasabuvir
28%
Diabetes Mellitus
28%
Disease Duration
5%
Diseases
28%
Fibrosis
8%
Hepatic Encephalopathy
11%
Hepatitis C
61%
Hepatitis C Virus
84%
Hepatitis C Virus Genotype 1
14%
Host Factor
28%
Infection Rate
5%
Intestinal Failure
99%
Liver Cell Carcinoma
33%
Liver Cirrhosis
36%
Neoplasm
5%
Neurotoxicity
11%
Nonalcoholic Fatty Liver
12%
Ombitasvir
28%
Paritaprevir
28%
Peginterferon
9%
Postoperative Complication
9%
Prevalence
33%
Proteinase Inhibitor
33%
Recurrent Disease
30%
Remission
28%
Retinol
14%
Retrospective Study
7%
Ribavirin
28%
Ritonavir
28%
Side Effect
33%
Trace Element
9%
Viral Clearance
7%
Virus Carrier
5%
Vitamin D
14%